Showing posts with label Fibromyalgia. Show all posts
Showing posts with label Fibromyalgia. Show all posts

Sunday, February 2, 2020

Fibromyalgia Syndrome: A Case Report on Controlled Remission of Symptoms by a Dietary Strategy



Fibromyalgia Syndrome: A Case Report on Controlled Remission of Symptoms by a Dietary Strategy

  • 1Department of Biomedical Sciences, University of Padova, Padova, Italy
  • 2Neurological Department, Ospedale Niguarda Ca’ Granda, Milan, Italy
A 34-year-old woman suffered from significant chronic pain, depression, non-restorative sleep, chronic fatigue, severe morning stiffness, leg cramps, irritable bowel syndrome, hypersensitivity to cold, concentration difficulties, and forgetfulness. Blood tests were negative for rheumatic disorders. The patient was diagnosed with Fibromyalgia syndrome (FMS). Due to the lack of effectiveness of pharmacological therapies in FMS, she approached a novel metabolic proposal for the symptomatic remission. Its core idea is supporting serotonin synthesis by allowing a proper absorption of tryptophan assumed with food, while avoiding, or at least minimizing the presence of interfering non-absorbed molecules, such as fructose and sorbitol. Such a strategy resulted in a rapid improvement of symptoms after only few days on diet, up to the remission of most symptoms in 2 months. Depression, widespread chronic pain, chronic fatigue, non-restorative sleep, morning stiffness, and the majority of the comorbidities remitted. Energy and vitality were recovered by the patient as prior to the onset of the disease, reverting the occupational and social disabilities. The patient episodically challenged herself breaking the dietary protocol leading to its negative test and to the evaluation of its benefit. These breaks correlated with the recurrence of the symptoms, supporting the correctness of the biochemical hypothesis underlying the diet design toward remission of symptoms, but not as a final cure. We propose this as a low risk and accessible therapeutic protocol for the symptomatic remission in FMS with virtually no costs other than those related to vitamin and mineral salt supplements in case of deficiencies. A pilot study is required to further ground this metabolic approach, and to finally evaluate its inclusion in the guidelines for clinical management of FMS.


Thursday, November 12, 2015

Shirley applying PACE trial logic to a broken ankle ...





It's not the broken ankle but the thoughts about the ankle
that make it painful to jog.



PS by Janet: recovery depends on not speaking to others with broken ankles ...

Saturday, July 25, 2015

Gene expression factors differentiate fibromyalgia, ME/CFS, depression and healthy controls from each other

@ PubMed:

  Arthritis Care Res (Hoboken).  2015 Jun 19. doi: 10.1002/acr.22639. [Epub ahead of print]

  Gene expression factor analysis to differentiate pathways linked to fibromyalgia, chronic fatigue syndrome, and depression in a diverse patient sample.

  Iacob E, Light AR, Donaldson GW, Okifuji A, Hughen RW, White AT, Light KC.

  Abstract

  OBJECTIVE:
  To determine if independent candidate genes can be grouped into meaningful biological factors and if these factors are associated with the diagnosis of chronic fatigue syndrome (CFS) and fibromyalgia (FMS) while controlling for co-morbid depression, sex, and age.

  METHODS:
  We included leukocyte mRNA gene expression from a total of 261 individuals including healthy controls (n=61), patients with FMS only (n=15), CFS only (n=33), co-morbid CFS and FMS (n=79), and medication-resistant (n=42) or medication-responsive (n=31) depression. We used Exploratory Factor Analysis (EFA) on 34 candidate genes to determine factor scores and regression analysis to examine if these factors were associated with specific diagnoses.

  RESULTS:
  EFA resulted in four independent factors with minimal overlap of genes between factors explaining 51% of the variance. We labeled these factors by function as: 1) Purinergic and cellular modulators; 2) Neuronal growth and immune function; 3) Nociception and stress mediators; 4) Energy and mitochondrial function. Regression analysis predicting these biological factors using FMS, CFS, depression severity, age, and sex revealed that greater expression in Factors 1 and 3 was positively associated with CFS and negatively associated with depression severity (QIDS score), but not associated with FMS.

  CONCLUSION:
  Expression of candidate genes can be grouped into meaningful clusters, and CFS and depression are associated with the same 2 clusters but in opposite directions when controlling for co-morbid FMS. Given high co-morbid disease and interrelationships between biomarkers, EFA may help determine patient subgroups in this population based on gene expression.

 

Sunday, June 28, 2015

Research shows that mostly raw vegetarian diet helps many patients with Fibromyalgia

@ PubMed:

  BMC Complement Altern Med. 2001;1:7. Epub 2001 Sep 26. Fibromyalgia syndrome improved using a mostly raw vegetarian diet: an observational study. Donaldson MS1, Speight N, Loomis S .Author information

  Abstract

  BACKGROUND: Fibromyalgia engulfs patients in a downward, reinforcing cycle of unrestorative sleep, chronic pain, fatigue, inactivity, and depression. In this study we tested whether a mostly raw vegetarian diet would significantly improve fibromyalgia symptoms.

  METHODS: Thirty people participated in a dietary intervention using a mostly raw, pure vegetarian diet. The diet consisted of raw fruits, salads, carrot juice, tubers, grain products, nuts, seeds, and a dehydrated barley grass juice product. Outcomes measured were dietary intake, the fibromyalgia impact questionnaire (FIQ), SF-36 health survey, a quality of life survey (QOLS), and physical performance measurements.

  RESULTS: Twenty-six subjects returned dietary surveys at 2 months; 20 subjects returned surveys at the beginning, end, and at either 2 or 4 months of intervention; 3 subjects were lost to follow-up. The mean FIQ score (n = 20) was reduced 46% from 51 to 28. Seven of the 8 SF-36 subscales, bodily pain being the exception, showed significant improvement (n = 20, all P for trend < 0.01). The QOLS, scaled from 0 to 7, rose from 3.9 initially to 4.9 at 7 months (n = 20, P for trend 0.000001). Significant improvements (n = 18, P < 0.03, paired t-test) were seen in shoulder pain at rest and after motion, abduction range of motion of shoulder, flexibility, chair test, and 6-minute walk. 19 of 30 subjects were classified as responders, with significant improvement on all measured outcomes, compared to no improvement among non-responders. At 7 months responders' SF-36 scores for all scales except bodily pain were no longer statistically different from norms for women ages 45-54.

  CONCLUSION: This dietary intervention shows that many fibromyalgia subjects can be helped by a mostly raw vegetarian diet.      

  PMID:   * 11602026   * [PubMed - indexed for MEDLINE]   *       PMCID:   * PMC57816  *

  Free PMC Article @ PubMed:

 

Tuesday, May 19, 2015

Fibromyalgia now considered a lifelong central nervous system disorder

News-Medical.Net -Published on May 18, 2015:

  Fibromyalgia is the second most common rheumatic disorder behind osteoarthritis and, though still widely misunderstood, is now considered to be a lifelong central nervous system disorder, which is responsible for amplified pain that shoots through the body in those who suffer from it.

  Daniel Clauw, M.D., professor of anesthesiology, University of Michigan, analyzed the neurological basis for fibromyalgia in a plenary session address today at the American Pain Society Annual Scientific Meeting.

  "Fibromyalgia can be thought of both as a discreet disease and also as a final common pathway of pain centralization and chronification. Most people with this condition have lifelong histories of chronic pain throughout their bodies," said Clauw. "The condition can be hard to diagnose if one isn't familiar with classic symptoms because there isn't a single cause and no outward signs."

  Clauw explained that fibromyalgia pain comes more from the brain and spinal cord than from areas of the body in which someone may experience peripheral pain. The condition is believed to be associated with disturbances in how the brain processes pain and other sensory information. He said physicians should suspect fibromyalgia in patients with multifocal (mostly musculoskeletal) pain that is not fully explained by injury or inflammation.

  "Because pain pathways throughout the body are amplified in fibromyalgia patients, pain can occur anywhere, so chronic headaches, visceral pain and sensory hyper-responsiveness are common in people with this painful condition," said Clauw.

  More @ News-Medical.Net

Friday, November 15, 2013

The Independent: 10 best charity Christmas cards 2013, No 1. Invest in ME !!


The Independent, SALLY NEWALL Friday 15 November 2013:


It's almost time for the big festive mail-out - consider these charity cards. 100% of your money goes to the cause

1. Invest in ME
The charity ran a competition for ME patients and their carers to submit photos. We think this vibrant entry by Julie-Ann Gylaitis is a festive triumph.
£4.25 for 10
www.investinme.org

2. Artfelt
The arts programme at Sheffield Children's Hospital commissioned local artist Pete McKee to design their card this year. The result? A sweet but interesting little cartoon of McKee’s own dog Frank.  
£3.50 for 8

3. RNLI
The cartoonist Giles was a keen sailor and did lots of work for the RNLI. His designs are bestsellers for the charity.  

4. SPANA
Everyone’s favourite desert dweller has made it onto the front of the animal charity's card. Another design features some kissing tortoises. Pucker up.
£4 for 10  www.spana.org

5. Riders for Health
Ideal for motorbike fans but actually it’s just quite a cool design. The money goes to mobilising health workers in Africa, designed by one of the charity’s volunteers.

6. GOSH
This cute robin’s the work of Jacob, 6, a patient at Great Ormond Street.  
£4.50 for 10  www.shop.gosh.org

7. Child bereavement UK
Donated by artist Charlie Macksey, this dove design makes an elegant card.
£4.75 for 10 www.childbereavement.org

8. Sustrans
A nice cycling design from the charity that investing in helping people travel by foot, bike or public transport. Cyclists will like this one

9. Home Start
Kirstie Allsop commissioned this design for the charity. It’s by paper artist poppy chancellor and we think it makes a lovely snowflake.
£4.75 for 10, www.home-start.org.uk

10. Action medical research for children
Uninspired by many charity Christmas efforts, gallery owner Lynn Tait a gallery owner got card designers  to contribute a piece of their work exclusively to the medical research charity. This cycling Santa’s by Julie Hook.
£2.50 for six, www.action.org.uk

Wednesday, July 24, 2013

A bloodspot-based diagnostic test for fibromyalgia syndrome: changes in tryptophan catabolism pathway differentiate patients with FM from those with RA or OA


Paper

A bloodspot-based diagnostic test for fibromyalgia syndrome and related disorders

Show Affiliations
Analyst, 2013,138, 4453-4462

DOI: 10.1039/C3AN36615D
Received 05 Nov 2012, Accepted 03 Apr 2013
First published online 04 Apr 2013
Download Citation
Help
Access Denied
This content is free, please choose one of the three options provided in the Log in section to gain access.
 
Read more>>

Tuesday, February 28, 2012

dorsal root ganglia channelopathie associated with severe fibromyalgia

http://www.biomedcentral.com/1471-2474/13/23/abstract


A SCN9A gene-encoded dorsal root ganglia sodium channel polymorphism associated with severe fibromyalgia

Gilberto Vargas-Alarcon, Edith Alvarez-Leon, Jose-Manuel Fragoso, Angelica Vargas, Aline Martinez, Maite Vallejo and Manuel Martinez-Lavin

For all author emails, please log on.
BMC Musculoskeletal Disorders 2012, 13:23 doi:10.1186/1471-2474-13-23
Published: 20 February 2012

Abstract (provisional)

Background

A consistent line of investigation suggests that autonomic nervous system dysfunction may explain the multi-system features of fibromyalgia (FM); and that FM is a sympathetically maintained neuropathic pain syndrome. Dorsal root ganglia (DRG) are key sympathetic-nociceptive short-circuit sites. Sodium channels located in DRG (particularly Nav1.7) act as molecular gatekeepers for pain detection. Nav1.7 is encoded in gene SCN9A of chromosome 2q24.3 and is predominantly expressed in the DRG pain-sensing neurons and sympathetic ganglia neurons. Several SCN9A sodium channelopathies have been recognized as the cause of rare painful dysautonomic syndromes such as paroxysmal extreme pain disorder and primary erythromelalgia. The aim of this study was to search for an association between fibromyalgia and several SCN9A sodium channels gene polymorphisms.

Methods

We studied 73 Mexican women suffering from FM and 48 age-matched women who considered themselves healthy. All participants filled out the Fibromyalgia Impact Questionnaire (FIQ). Genomic DNA from whole blood containing EDTA was extracted by standard techniques. The following SCN9A single-nucleotide polymorphisms (SNP) were determined by 5' exonuclease TaqMan assays: rs4371369; rs4387806; rs4453709; rs4597545; rs6746030; rs6754031; rs7607967; rs12620053; rs12994338; and rs13017637.

Results

The frequency of the rs6754031 polymorphism was significantly different in both groups (P = 0.036) mostly due to an absence of the GG genotype in controls. Interestingly; patients with this rs6754031 GG genotype had higher FIQ scores (median = 80; percentile 25/75 = 69/88) than patients with the GT genotype (median = 63; percentile 25/75 = 58/73; P = 0.002) and the TT genotype (median = 71; percentile 25/75 = 64/77; P = 0.001).

Conclusion

In this ethnic group; a disabling form of FM is associated to a particular SCN9A sodium channel gene variant. These preliminary results raise the possibility that some patients with severe FM may have a dorsal root ganglia sodium channelopathy.

Thursday, February 16, 2012

Mitochondrial myopathy presenting as fibromyalgia




Mitochondrial myopathy presenting as fibromyalgia: a case report
Mishal Abdullah, Sahana Vishwanath, Amro Elbalkhi and Julian L. Ambrus
http://www.jmedicalcasereports.com/content/6/1/55/abstract
For all author emails, please log on.

MA: mishalabdullah@hotmail.com
SV: sahana_vishwanath@yahoo.com
AE: amrbalkhi@yahoo.com
JLAJr: jambrus@buffalo.edu

Journal of Medical Case Reports 2012, 6:55 doi:10.1186/1752-1947-6-55
Published: 10 February 2012
Abstract (provisional)
Introduction
To the best of our knowledge, we describe for the first time the case of a woman who met the diagnostic criteria for fibromyalgia, did not respond to therapy for that disorder, and was subsequently diagnosed by biochemical and genetic studies with a mitochondrial myopathy. Treatment of the mitochondrial myopathy resulted in resolution of symptoms. This case demonstrates that mitochondrial myopathy may present in an adult with a symptom complex consistent with fibromyalgia.

Case presentation
Our patient was a 41-year-old Caucasian woman with symptoms of fatigue, exercise intolerance, headache, and multiple trigger points. Treatment for fibromyalgia with a wide spectrum of medications including non-steroidal anti-inflammatory drugs, antidepressants, gabapentin and pregabalin had no impact on her symptoms. A six-minute walk study demonstrated an elevated lactic acid level (5mmol/L; normal <2mmol/L). Biochemical and genetic studies from a muscle biopsy revealed a mitochondrial myopathy. Our patient was started on a compound of coenzyme Q10 (ubiquinone) 200mg, creatine 1000mg, carnitine 200mg and folic acid 1mg to be taken four times a day. She gradually showed significant improvement in her symptoms over a course of several months.

Conclusions
This case demonstrates that adults diagnosed with fibromyalgia may have their symptom complex related to an adult onset mitochondrial myopathy. This is an important finding since treatment of mitochondrial myopathy resulted in resolution of symptoms.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.
_------------------------------------

http://www.jmedicalcasereports.com/content/pdf/1752-1947-6-55.pdf

Discussion
Mitochondrial myopathies are disorders characterized by morphological abnormalities of
muscle mitochondria. Accumulating evidence suggests that mitochondrial disorders are
among the most common inherited metabolic diseases [10]. Similar to fibromyalgia,
patients may present with muscle weakness, pain, fatigue and exercise intolerance that
progressively worsens over time.
Several steps are involved in Adenosine-5'-triphosphate (ATP) generation in the
mitochondria, and defects in any part of the cycle may impair energy production leading
to symptoms [11]. These abnormalities in generation and utilization of ATP can be
assessed by specific tests, which as in our patient pointed towards problems in energy
metabolism [12].

Genetic testing with sequencing of the mitochondrial genome and
chromosomal genes affecting mitochondrial function may also be pursued, as was
performed in our patient. Mutations in POLG1 and several mitochondrial genome
polymorphisms were noted. our patient was started on a regimen of coenzyme Q10 (Co-Q10;
ubiquinone), creatine, carnitine, folic acid and α-lipoic acid. Co-Q10 transports electrons
between complex I and complex III of the mitochondrial respiratory chain and has been
shown to improve mitochondrial function in several studies [13]. Creatine generates
additional ATP through the creatine phosphate shuttle. Carnitine enhances transport of
fatty acids into the mitochondria. Folic acid is a cofactor for several mitochondrial
enzymes, while α-lipoic acid is a strong antioxidant [14]. Although this treatment
regimen was started several years after symptom onset, within the first few months our
patient showed tremendous improvement. With continued therapy, her complaints
dissipated over several months, with a gradual but sustained resolution of all symptoms.

http://www.jmedicalcasereports.com/content/pdf/1752-1947-6-55.pdf

Friday, January 20, 2012

Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia

Roberta P da Cunha Ribeiro1, Hamilton Roschel1,2, Guilherme G Artioli1,2, Thalita Dassouki1, Luiz A Perandini1, Ana L Calich1, Ana L de Sá Pinto1, Fernanda R Lima1, Eloísa Bonfá1 and Bruno Gualano1,2*:

Corresponding author: Bruno Gualano gualano@usp.br Author Affiliations 1 Division of Rheumatology, School of Medicine, University of Sao Paulo, Brazil. Av. Dr. Arnaldo, 455, Cerqueira César, Brazil 2 School of Physical Education and Sport, University of Sao Paulo, Brazil. Av. Prof. Mello Moraes, 65, Butantã, Brazil For all author emails, please log on. Arthritis Research & Therapy 2011, 13:R190 doi:10.1186/ar3519


The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/13/6/R190 Received: 19 May 2011 Revisions received: 25 August 2011 Accepted: 18 November 2011 Published: 18 November 2011 © 2011 da Cunha Ribeiro et al.; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited


Abstract

Introduction
We aimed to gather knowledge on the cardiac autonomic modulation in patients with fibromyalgia (FM) in response to exercise and to investigate whether this population suffers from chronotropic incompetence (CI).


Methods
Fourteen women with FM (age: 46 ± 3 years; body mass index (BMI): 26.6 ± 1.4 kg/m2) and 14 gender-, BMI- (25.4 ± 1.3 kg/m2), and age-matched (age: 41 ± 4 years) healthy individuals (CTRL) took part in this cross-sectional study. A treadmill cardiorespiratory test was performed and heart-rate (HR) response during exercise was evaluated by the chronotropic reserve. HR recovery (deltaHRR) was defined as the difference between HR at peak exercise and at both first (deltaHRR1) and second (deltaHRR2) minutes after the exercise test.


Results

FM patients presented lower maximal oxygen consumption (VO2 max) when compared with healthy subjects (22 ± 1 versus CTRL: 32 ± 2 mL/kg/minute, respectively; P < 0.001). Additionally, FM patients presented lower chronotropic reserve (72.5 ± 5 versus CTRL: 106.1 ± 6, P < 0.001), deltaHRR1 (24.5 ± 3 versus CTRL: 32.6 ± 2, P = 0.059) and deltaHRR2 (34.3 ± 4 versus CTRL: 50.8 ± 3, P = 0.002) than their healthy peers. The prevalence of CI was 57.1% among patients with FM.


Conclusions
Patients with FM who undertook a graded exercise test may present CI and delayed HR recovery, both being indicative of cardiac autonomic impairment and higher risk of cardiovascular events and mortality.


Wednesday, January 18, 2012

Oh Lord, Please Don’t Let Me Be Misunderstood

Oh Lord, Please Don’t Let Me Be Misunderstood 

by Margaret Williams         16th January 20121

Professor Simon Wessely has recently published his own account of his involvement since the late 1980s with what he refers to as Chronic Fatigue Syndrome but does not clarify that he and his colleagues regard CFS as synonymous with ME and that they regard – and treat—it as a behavioural disorder (“CFS Personal Story”: simonwessely.com/faq.html).

His story as published on his new website makes a smooth and impressive read, at least for the uninitiated, as it refers to numerous biomedical studies with which Wessely says he was involved during his “CFS” career.

What he fails to make clear is the number of those biomedical studies that had negative findings, or that he uses the Oxford case definition that specifically excludes those with a neurological disorder such as ME, so he may be studying only those with unexplained “fatigue”.

Equally, he claims “considerable success” with cognitive behavioural therapy but again he does not explain the cardinal importance of case definition.

Wessely states that he is “proud” of having contributed to neuroendocrine studies and seems to be claiming the honour for having discovered HPA axis dysfunction in “CFS”, whereas this was first demonstrated by Mark Demitrack in the US (Journal of Clinical Endocrinology and Metabolism 1991:73:6:1224-1234; Biol Psychiatry 1992:32:1065-1077).

Wessely specifically mentions Professor Tony Cleare (a member of Wessely’s group) and his work on neuroendocrine aspects of CFS, but does not explain that Cleare regards the disorder as being “most likely of biopsychosocial origin”, concluding that there is “no evidence for a specific or uniform dysfunction of the HPA axis” and that confounding factors such as inactivity and psychiatric comorbidity may influence the observed endocrine changes (Endocrine Reviews 2003:24:236-252). Cleare is also on record as stating that “HPA axis changes can be reversed by modifying behavioural features of the illness, such as inactivity (and) deconditioning” and that “current evidence suggests that neuroendocrine changes are not a central core of the condition, but occur…at least partly as a response to certain features of the illness such as …physical deconditioning” (TRENDS in Endocrinology and Metabolism 2004:15:2).

Notably, Wessely fails to report his own view on the cortisol abnormality: -

“I will argue that this line here represents not the line between low and high cortisol responses…but the line between real and unreal illness” - Simon Wessely - Microbes, Mental illness, the Media and ME: The Construction of Disease; 9th Eliot Slater lecture given at The Institute of Psychiatry, 12th May 1994
Wessely mentions the immunological studies with which he has been involved, but again he does not explain that his group failed to find the immunological abnormalities documented by experts such as Professor Nancy Klimas, nor that he argues against immunological testing, for example:

“Though disordered immunity and persisting viral infection have recently attracted attention, it is important that immunologists do not deflect attention away from the wider (ie. psychiatric) aspects of the chronic fatigue/postviral syndrome” (Anthony David, Simon Wessely, Anthony Pelosi. Lancet 1988: July 9th: 100-101).
Notably, in his “CFS Personal Story” Wessely says:

“We showed that immune dysfunction didn’t relate to clinical outcomes” but experts have found the exact opposite, for example: “We demonstrated changes in different immunological parameters, each of which correlated with particular aspects of disease symptomatology” (Hassan I, Weir WRC et al. Clin Immunol & Immunopathol 1998:87:1:60-67); “The findings suggest that the degree of cellular immune activation is associated with severity of physical symptoms” (Immunological Status Correlates with Severity of Physical Symptoms in Chronic Fatigue Syndrome Patients. S Wagner, N Klimas et al; Fourth International AACFS Research & Clinical Conference 1998; abstract page 28) and “Among (ME)CFS subjects, those who had been sick longer had higher rates of autoantibodies” (S Vernon et al. Journal of Autoimmune Diseases 2005: May 25th: 2:5).


Wessely mentions his work looking at HLA phenotypes but does not reveal that his team found no association with any specific phenotype, whereas others have shown direct linkage:

“A significant association between CFIDS and  the presence of HLA-DQ3 was noted” (RH Keller, N Klimas et al. Clin Inf Dis 1994:18: (Suppl 1): S154-S156) and “The frequency of the HLA-DQ1 antigen was increased in patients compared to controls. This association between (ME)CFS and the HLA-DQ1 antigen translates into a relative risk of 3.2” (RS Schacterle, Anthony L Komaroff et al. JCFS 2004:11(4):33-42).




Wessely also fails to mention that in the 1996 Joint Royal Colleges’ Report on CFS his advice to Government bodies was that the reported biomedical abnormalities “should not deflect the clinician away from the biopsychosocial approach and should not focus attention towards a search for an ‘organic’ cause”, or his recommendation that no advanced tests should be carried out on these patients when it is those very tests that reveal the organic nature of the disorder (Joint Royal Colleges’ Report 1996: CR54).



He refers to his work on vitamin levels without mentioning his disparaging dismissal of vitamin supplementation or his unsupported conclusion that “many” people with “CFS” are taking vitamin B supplementation with no evidence of benefit (JRSM 1999:92:183-185).



Wessely concedes that he has changed his “writing style” but does not appear to comprehend the extent to which his earlier published views are perceived almost universally as being denigratory and sometimes mocking (as is to be found, for example, in the audiotape and his own notes for his 1994 Eliot Slater lecture), nor does he mention the harm in the form of medical rejection and dismissal, as well as the financial hardship, that have resulted from the widespread adoption of his views by the medical fraternity, government departments and private health insurers.

Indeed, he entirely fails to mention his published views, for example:

“neurasthenia would readily suffice for ME”; “It seems that ME sufferers prefer to feel that they have a ‘real’ disease – it is better for their self-esteem”;  “many patients become…over-sensitised to physical sensations”; “Blaming symptoms on a viral infection conveys certain advantages, irrespective of its validity…It is also beneficial to self-esteem by protecting the individual from guilt and blame”; that patients obtain “secondary gain” by “adopting the sick role”; that “fear of illness is an important part of (the disorder)”; that patients are not suffering from any organic disorder because he believes their symptoms have no anatomical or physiological basis; that “The term ME may mislead patients into believing they have a serious and specific pathological process” and that “Several studies (often Wessely’s own) suggest that poor outcome is associated with social, psychological and cultural factors”.

Wessely says in his account of his involvement with “CFS”:

“I remain proud of the work myself and colleagues did in the early days of CFS…But there has been a downside”, and here he appears to seek sympathy from his readers by referring to alleged threats made to him by “activists”.

He continues:

“Right from the start, myself and all my colleagues had from the start (sic) been targeted by a small group of activists who (sic) mission was, and still is, to impede our work in as much as they are able.  Thankfully… they haven’t succeeded and won’t”.



He goes on to say:

Wednesday, December 7, 2011

BC Women’s Hospital new $2 million medical centre for Lyme, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and other complex diseases

Posted by: Pamela Fayerman, December 6, 2011: The BC government pledged $2 million eight months ago for a new clinic where those with lyme disease and other complex, chronic diseases could go for help in managing their many symptoms. Today the clinic has a home but no opening date. That’s because experts and other stakeholders – including patients themselves – are still being consulted on how to deliver the services.

It’s probably wise to tread carefully because in the highly emotional, frustrating and uncertain world that is the everyday reality for patients like these, such a clinic must be a welcoming place offering hope, help and shared decision making.

Lyme disease, fibromyalgia, chronic fatigue and other complex diseases have  always been contentious, partly because of ambiguous symptoms and the difficulty with diagnostic tools. The announcement about the clinic came just days after I wrote this story about how doctors in BC are under-reporting lyme disease cases and not so great about diagnosing or treating the disease. This is not unique to Vancouver.

There are tens of thousands of patients across BC with debilitating chronic diseases in which the cause is unknown, but may have been triggered by an infectious agent. Fatigue, pain, stiffness and insomnia are often hallmark symptoms.  Gwen Barlee, a chronic lyme disease patient/advocate told me today she’s cautiously optimistic about the clinic.

“But the proof will be in the pudding. Who will run the clinic?   We need to get beyond the outdated way of treating, or not treating Lyme disease, so we need the clinic to be staffed with professionals who aren’t afraid of the politics surrounding lyme disease and are willing to treat based on symptoms, and not rely on a flawed blood testing model.

“The BC government has a chance to do this right. I hope they will seize the moment. They need to work closely with CanLyme and lyme disease patients instead of marginalizing people who are living with this disease. 

“I hope the BC clinic can lead the way in Canada with a proactive, open and inclusive approach to treating this illness. Of course the clinic is only one part of the equation – we need the BC government to implement the recommendations from the (Brian) Schmidt report - so far, I see no evidence that is happening, and that makes me concerned,” she said.

Here’s the press release about the new clinic:

“BC Women’s Hospital & Health Centre will be home to a new clinic that will address complex diseases such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Lyme disease and Fibromyalgia, which often lead to disability for British Columbians.

British Columbia is taking a leading role within Canada with the clinic and its associated research program.  The establishment of the clinic is made possible with the direct investment of $2 million from the BC Ministry of Health announced earlier this year.  The clinic will work with patients and family physicians from across the province to provide care for people in addition to learning more about these complex diseases.

The clinic and its research program are expected to support clinicians and researchers in their pursuit of the discovery of causes, diagnosis and potential treatments for these types of diseases. Read more>>

Tuesday, December 6, 2011

Fibromyalgia is associated with multiple changes in the brain giving the long-held “it is all in your head” view, a new meaning

Pain Research and Treatment
Volume 2012 (2012), Article ID 585419, 8 pages doi:10.1155/2012/585419:


Review Article
Neurobiology Underlying Fibromyalgia Symptoms
Marta Ceko,1,2 M. Catherine Bushnell,1,2,3 and Richard H. Gracely4
1Alan Edwards Centre for Research on Pain, McGill University, 3640 University Street, Room M19, Montreal, QC, H2A 1C1, Canada
2Department of Neurology & Neurosurgery, McGill University, 3640 University Street, Room M19, Montreal, QC, H2A 1C1, Canada
3Department of Anesthesia, McGill University, 3640 University Street, Room M19, Montreal, QC, H2A 1C1, Canada
4Center for Neurosensory Disorders, University of North Carolina, CB No. 7280, 3330 Thurston Building, Chapel Hill, NC 27599, USA

Received 27 April 2011; Accepted 23 August 2011

Academic Editor: Muhammad B. Yunus

Copyright © 2012 Marta Ceko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Fibromyalgia is characterized by chronic widespread pain, clinical symptoms that include cognitive and sleep disturbances, and other abnormalities such as increased sensitivity to painful stimuli, increased sensitivity to multiple sensory modalities, and altered pain modulatory mechanisms. Here we relate experimental findings of fibromyalgia symptoms to anatomical and functional brain changes. Neuroimaging studies show augmented sensory processing in pain-related areas, which, together with gray matter decreases and neurochemical abnormalities in areas related to pain modulation, supports the psychophysical evidence of altered pain perception and inhibition. Gray matter decreases in areas related to emotional decision making and working memory suggest that cognitive disturbances could be related to brain alterations. Altered levels of neurotransmitters involved in sleep regulation link disordered sleep to neurochemical abnormalities. Thus, current evidence supports the view that at least some fibromyalgia symptoms are associated with brain dysfunctions or alterations, giving the long-held “it is all in your head” view of the disorder a new meaning.



>___<

3.4. What Do the Psychophysical, Cognitive, and Neuroimaging Studies Tell Us about the Neurobiology Underlying FM Symptoms?

The wealth of experimental evidence showing that FM patients are hypersensitive to painful stimuli, as well as unpleasant stimuli from other sensory modalities, in conjunction with functional brain imaging data showing increased stimulus-evoked activation throughout nociceptive pathways, shows that the defining symptom of FM—increased pain—is in fact real and not just a response bias of the patients. The finding that perception is increased in multiple modalities speaks against the hypothesis that FM pain is due to an upregulation of peripheral nociceptive processes. Further, psychophysical evidence that descending modulatory systems are altered in FM patients supports the opposing idea that FM symptoms are at least in part caused by alterations in CNS processing of the pain signal, including a dysregulation of pain modulatory systems. Nevertheless, the apparent dysregulation within these systems could be caused and/or perpetuated by a tonic activation related to the presence of ongoing widespread pain, so that the systems are saturated and cannot regulate further in response to external stimuli.

Since similar descending control systems, including attentional and emotional regulatory circuitry, affect multiple sensory modalities [113–119], a dysfunction (or saturation) in these systems could lead to the hypersensitivity in multiple sensory modalities. FM patients show reduced habituation to nonpainful tactile stimuli and increased cortical response to intense auditory stimuli, both of which have been linked to deficient inhibition of incoming sensory stimuli [120, 121]. Also in support of the idea of a central dysregulation or saturation of pain modulation are changes in the opioid and dopamine neurotransmitter systems, both known to be involved in hedonic regulation [122].

Finally, the findings that FM patients not only perceive themselves to have altered memory and concentration (“fibrofog”), but also in fact perform poorly on multiple cognitive tests, even when depression is excluded as a contributing factor, suggest that there are alterations in brain function. The anatomical brain imaging studies that show reductions in gray matter in frontal regions important for cognitive function further indicate that this common symptom of FM is based on altered brain function. Together, the experimental evidence provides strong support for the idea that FM symptoms are related to dysfunctions in the central nervous system. The cause of these changes cannot be deduced from the available evidence, as it is correlational in nature. Did long-term ongoing pain cause the changes or did the changes cause the pain? Without a relevant animal model or long-term longitudinal studies, we cannot answer these questions. Nevertheless, we can at least say that fibromyalgia is real and that it is associated with multiple changes in the brain.

LinkWithin

Related Posts with Thumbnails